0001415889-23-007476.txt : 20230505 0001415889-23-007476.hdr.sgml : 20230505 20230505180012 ACCESSION NUMBER: 0001415889-23-007476 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230503 FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Verwijs Marinus CENTRAL INDEX KEY: 0001916553 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 23895276 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-05052023_060501.xml X0407 4 2023-05-03 0001798749 Aerovate Therapeutics, Inc. AVTE 0001916553 Verwijs Marinus C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false SENIOR VICE PRESIDENT, CMC 0 Common Stock 2023-05-03 4 S 0 759 20.7897 D 0 D The sales reported in this Form 4 were effected pursuant to E*TRADE Securities LLC's Quicksale Trading Plan elected by the reporting person on July 11, 2022. Includes 759 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.78 to $20.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. /s/ George A. Eldridge, Attorney-in-Fact 2023-05-03